ILSE Intralase Corp (MM)

IntraLase(R) Corp. (NASDAQ:ILSE) announced today that it will report its 2006 first quarter results on Thursday, April 27, 2006. A news release will be issued and will also be posted on the company's Web site at www.intralase.com. Also on April 27, IntraLase will hold an investor conference call at 11 a.m. Eastern time to discuss the company's results. Hosting the call will be Robert J. Palmisano, president and chief executive officer, and Shelley B. Thunen, executive vice president and chief financial officer. Members of the news media may "listen only" to the conference call. The conference call will be webcast live and can be accessed on the IntraLase Web site. The webcast is available to both institutional and individual investors. Individual investors can access the webcast at: www.fulldisclosure.com. Institutional investors can access the webcast via a password-protected event-management site at www.streetevents.com. The live call may also be accessed by telephone at 866-825-3354 or for international parties at 617-213-8063 and entering the confirmation code 16974298 between 10:50 a.m. and 11 a.m. Eastern time. The webcast will be archived and available for replay until 5 p.m. Pacific time on May 4, 2006. A telephone rebroadcast of the call may be accessed April 27, 2006, beginning at 1 p.m. Eastern time for a one-week period by calling 888-286-8010 or for international parties 617-801-6888 and entering confirmation code 18731904. About IntraLase Corp. IntraLase designs, develops, and manufactures an ultra-fast laser that is revolutionizing refractive and corneal surgery by creating safe and more precise corneal incisions. Delivering on the promise of ophthalmic laser technology, the IntraLase FS laser, related software, and disposable devices replace the hand-held microkeratome blade used during LASIK surgery. The unsurpassed accuracy of IntraLase's computer-controlled femtosecond laser has been shown to improve safety profiles and visual outcomes when used during LASIK. Additionally, the IntraLase FS laser creates precision-designed intracorneal incisions that when combined can be used during lamellar and penetrating keratoplasties and intrastromal ring implantation. IntraLase is presently in the process of commercializing applications of its technology in the treatment of corneal diseases that require corneal transplant surgery. The company's proprietary laser and disposable patient interfaces are presently marketed throughout the United States and 26 other countries. IntraLase has headquarters and manufactures its products in Irvine. For additional information, visit the company's Web site: www.intralase.com.